Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Conditions
Interventions
VP20621
VP20621
+2 more
Locations
59
United States
Modesto, California, United States
Palm Desert, California, United States
Sacramento, California, United States
Aurora, Colorado, United States
Hartford, Connecticut, United States
Bay Pines, Florida, United States
Start Date
June 27, 2011
Primary Completion Date
June 11, 2013
Completion Date
June 11, 2013
Last Updated
June 10, 2021
NCT06237452
NCT04014413
NCT04003818
NCT05826418
NCT04100603
NCT03350711
Lead Sponsor
Shire
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions